Cyclerion Therapeutics logo
Cyclerion Therapeutics CYCN
$ 3.0 -0.66%

Annual report 2024
added 11-12-2025

report update icon

Cyclerion Therapeutics Accounts Payables 2011-2026 | CYCN

Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.
Main types of accounts payable
Type of liabilityExample
To suppliers and contractorsGoods received but not yet paid for
Taxes and feesVAT, income tax, etc., not paid on time
SalariesEmployee wages not paid
To budgetsInsurance contributions to funds not paid
To foundersFounders provided borrowed funds
To banksOverdue loan payments
OtherFines, penalties, forfeits, customer prepayments, etc.

Impact on the company's financial performance
  1. Liquidity and solvency
    Accounts payable are part of short-term liabilities, so they affect liquidity ratios
  2. Financial stability
    The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence
  3. Capital turnover
    Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals)
  4. Risks and reputation
    Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated

Annual Accounts Payables Cyclerion Therapeutics

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
390 K 1.2 M 2.97 M 1.83 M 1.15 M 3.23 M - - - - - - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
3.23 M 390 K 1.79 M

Quarterly Accounts Payables Cyclerion Therapeutics

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
480 K 462 K 483 K 390 K 304 K 651 K 741 K 1.2 M 814 K 1.86 M - 2.97 M 1.64 M 2.77 M 2.52 M 1.83 M 1.17 M 1.39 M 1.1 M 1.15 M 1.15 M 1.15 M 1.15 M 3.23 M 3.23 M 3.23 M 3.23 M 2.78 M 2.78 M 2.78 M 2.78 M - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
3.23 M 304 K 1.71 M

Accounts Payables of other stocks in the Biotechnology industry

Issuer Accounts Payables Price % 24h Market Cap Country
Allakos Allakos
ALLK
1.76 M - - $ 28.6 M usaUSA
AlloVir AlloVir
ALVR
1.28 M - 4.14 % $ 49.1 M usaUSA
I-Mab I-Mab
IMAB
570 M - - $ 866 M chinaChina
Applied Molecular Transport Applied Molecular Transport
AMTI
1.58 M - - $ 10.1 M usaUSA
Applied Therapeutics Applied Therapeutics
APLT
1.74 M - - $ 8.42 M usaUSA
Aptinyx Aptinyx
APTX
724 K - -39.0 % $ 4.57 M usaUSA
Advaxis Advaxis
ADXS
6.08 M - -9.65 % $ 45.9 M usaUSA
Akouos Akouos
AKUS
1.28 M - 0.23 % $ 488 M usaUSA
Aligos Therapeutics Aligos Therapeutics
ALGS
3.98 M $ 6.51 -2.54 % $ 64.4 M usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
32.6 M $ 22.92 0.17 % $ 1.07 B usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
78 K - -52.27 % $ 4.45 M usaUSA
Aravive Aravive
ARAV
8.76 M - -13.39 % $ 1.45 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
561 K $ 3.0 -1.32 % $ 4.94 M israelIsrael
AgeX Therapeutics AgeX Therapeutics
AGE
1.93 M - -10.17 % $ 12.2 K usaUSA
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
7.07 M - -2.5 % $ 5.88 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
677 K - - $ 1.01 B usaUSA
Akebia Therapeutics Akebia Therapeutics
AKBA
21.2 M $ 1.43 1.78 % $ 368 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
8.11 M - -4.8 % $ 255 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
4.08 M - - $ 7.46 M israelIsrael
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
2.91 M - - $ 26.5 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
479 M - 0.49 % $ 251 B cayman-islandsCayman-islands
Aquestive Therapeutics Aquestive Therapeutics
AQST
29.9 M $ 4.24 -1.85 % $ 453 M usaUSA
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
12.5 M $ 24.47 -0.24 % $ 3.11 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
611 K - 1.93 % $ 17.4 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
3.08 M $ 1.58 -1.25 % $ 420 M britainBritain
Aptose Biosciences Aptose Biosciences
APTO
2.91 M - -45.71 % $ 1.2 M canadaCanada
BioXcel Therapeutics BioXcel Therapeutics
BTAI
14.7 M $ 1.2 4.35 % $ 14.6 M usaUSA
AVROBIO AVROBIO
AVRO
27 K - 1083.1 % $ 745 M usaUSA
Cabaletta Bio Cabaletta Bio
CABA
6.64 M $ 3.31 -3.92 % $ 333 M usaUSA
bluebird bio bluebird bio
BLUE
18.5 M - - $ 546 M usaUSA
Fennec Pharmaceuticals Fennec Pharmaceuticals
FENC
4.64 M $ 6.73 -0.88 % $ 192 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
9.03 M - - $ 3.67 B usaUSA
CymaBay Therapeutics CymaBay Therapeutics
CBAY
3.83 M - - $ 3.45 B usaUSA
Cidara Therapeutics Cidara Therapeutics
CDTX
3.61 M - - $ 1.41 B usaUSA
ChromaDex Corporation ChromaDex Corporation
CDXC
10.8 M - -0.88 % $ 598 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
1.03 M - 3.16 % $ 1.9 M usaUSA
ContraFect Corporation ContraFect Corporation
CFRX
13.7 M - -5.16 % $ 5.39 M usaUSA